Navigation Links
Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
Date:7/18/2013

associated with CDI-related stays in the hospital were $8.2 billion in the U.S. during 2009. CDI is a rising global HAI problem in which the toxins produced by C. difficile bacteria result in diarrhea (C. difficile-associated diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the lower GI tract) that can lead to death. CDI is a major, unintended risk associated with the prophylactic or therapeutic use of intravenous antibiotics, which may alter the natural balance of microflora that normally protect the GI tract, leading to C. difficile overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions including the administration of chemotherapy, and advanced age.

CDI is a widespread and often drug resistant infectious disease, and it is estimated that 1.1 million patients are infected with C. diff annually in the U.S.* Controlling the spread of CDI has proven challenging, as the C. difficile spores are easily transferred to patients via normal contact with healthcare personnel and other inanimate objects. There is currently no vaccine or approved product for the prevention of C. diff infection.

About Fujifilm Diosynth Biotechnologies (http://www.fujifilmdiosynth.com)

FUJIFILM Diosynth Biotechnologies UK Limited is an industry leading biologics Contract Development and Manufacturing Organization. Fujifilm Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from microbial and mammalian cell line development, including its proprietary pAVEway™ system, to process development, analytical develo
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
2. Synthetic Biologics to Present at OneMedForum New York 2013
3. New England Biolabs supports iGEM synthetic biology competition
4. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
5. Intrexon Organizes Around New Synthetic Biology Markets
6. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
7. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
8. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
9. Top Ten Suppliers of Synthetic Biology Technology
10. Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics Scientific Advisory Board
11. Discovery in synthetic biology takes us a step closer to new industrial revolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , ATLANTA and LONDON, Sept. 10 ... biological medical device and cardiovascular tissue processing company, today announced the ... Matrix, which received CE mark approval in August 2009. BioFoam was ... supplemental measure to promote hemostasis (a complex process that stops bleeding) ...
... WATERTOWN, Mass., Sept. 10 Tetraphase Pharmaceuticals ... technology announced today that it will present three (3) ... and antibacterial activity of analogs from several novel classes ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in ...
... BALTIMORE, Sept. 10 Champions Biotechnology, Inc. ... oncology services division assists physicians by providing personalized treatment options ... with PinnacleCare , the pioneer and the ... , PinnacleCare will offer Champions, personalized oncology services ...
Cached Biology Technology:CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 4
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... July 23, 2013 The goal of smart cities ... performance, efficiency and functionality. This is expressed through an ... of the overall city experience.  Cities are hoping to ... city projects to ultimately drive economic growth. Some key ...
... in the July issue of the Journal of ... super-infections like pneumonia with influenza. The research was led ... infectious disease specialist who is also chair of the ... Science Center and adjunct faculty at St. Jude Children,s ...
... NY. -- The use of central nervous system fetal ... cells for transplantation procedures aimed at restoring damage done ... tissue microbial contaminants have been known to cause brain ... team from Germany has developed a "washing" technique that ...
Cached Biology News:Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 2Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 3Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 4Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 5New protocol developed to decontaminate human fetal tissues used for cell transplantation 2
... for the rapid purification of linear 100 bp ... DNA band is excised from an,agarose gel and ... base of the column are a series of ... back while allowing DNA to selectively pass through ...
... is Tecans state-of-the-art software for all your ... scheduling in a single, scalable software package. ... consistent, simplifying the control of all Freedom ... Freedom EVO 100 with one liquid handling ...
...
... Isolation Kit provides all the reagents ... vesicle fraction. The isolation procedure involves ... synaptosomes, and differential centrifugation followed by ... also contains an antibody specific for ...
Biology Products: